Evidence map›Paper›PMID 26797122›Full record

ArticleThe Journal of biological chemistry2016

A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.

Xiaodong Gu, Zhiping Wu, Ying Huang, Matthew A Wagner, Camelia Baleanu-Gogonea, Ryan A Mehl, Jennifer A Buffa, Anthony J DiDonato, Leah B Hazen, Paul L Fox and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Molecular dynamics simulations of lipid nanodiscs.Biochimica et biophysica acta. Biomembranes · 2018
    Article
  7. Article
  8. Tertiary structure of apolipoprotein A-I in nascent high-density lipoproteins.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Xiaodong GuFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Zhiping WuFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Ying HuangFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Matthew A WagnerFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Camelia Baleanu-GogoneaFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Ryan A Mehlthe Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon 97331, and.
Jennifer A BuffaFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Anthony J DiDonatoFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Leah B HazenFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Paul L FoxFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Valentin GogoneaFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and the Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115.
John S Parksthe Sections on Molecular Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157.
Joseph A DiDonatoFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and.
Stanley L HazenFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute, and the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, hazens@ccf.org.
Cleveland Clinic · USCleveland State University · USOregon State University · USWake Forest University · US

Funding

Structural Determinants Of Ceruloplasmin Inflammatory ActivityP01HL076491 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI PLOW, EDWARD FRANKLIN · 2004 to 2019
$27.3M
The Role of Hepatocyte ABCA1 in Lipid Mobilization and TransportR01HL119962 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PARKS, JOHN S · 2013 to 2022
$3.9M
Equipment supplement: Defining Roles Of NitroTyrosine In Disease Via Genetic Code ExpansionR01GM114653 · NIGMS · OREGON STATE UNIVERSITY · PI MEHL, RYAN A · 2015 to 2024
$2.6M
NHLBI NIH HHS P01 HL076491NHLBI NIH HHS R01 HL119962NIGMS NIH HHS R01 GM114653
6 · The paper itself

Abstract

The interaction of lecithin-cholesterol acyltransferase (LCAT) with apolipoprotein A-I (apoA-I) plays a critical role in high-density lipoprotein (HDL) maturation. We previously identified a highly solvent-exposed apoA-I loop domain (Leu(159)-Leu(170)) in nascent HDL, the so-called "solar flare" (SF) region, and proposed that it serves as an LCAT docking site (Wu, Z., Wagner, M. A., Zheng, L., Parks, J. S., Shy, J. M., 3rd, Smith, J. D., Gogonea, V., and Hazen, S. L. (2007) Nat. Struct. Mol. Biol. 14, 861-868). The stability and role of the SF domain of apoA-I in supporting HDL binding and activation of LCAT are debated. Here we show by site-directed mutagenesis that multiple residues within the SF region (Pro(165), Tyr(166), Ser(167), and Asp(168)) of apoA-I are critical for both LCAT binding to HDL and LCAT catalytic efficiency. The critical role for possible hydrogen bond interaction at apoA-I Tyr(166) was further supported using reconstituted HDL generated from apoA-I mutants (Tyr(166) → Glu or Asn), which showed preservation in both LCAT binding affinity and catalytic efficiency. Moreover, the in vivo functional significance of NO2-Tyr(166)-apoA-I, a specific post-translational modification on apoA-I that is abundant within human atherosclerotic plaque, was further investigated by using the recombinant protein generated from E. coli containing a mutated orthogonal tRNA synthetase/tRNACUA pair enabling site-specific insertion of the unnatural amino acid into apoA-I. NO2-Tyr(166)-apoA-I, after subcutaneous injection into hLCAT(Tg/Tg), apoA-I(-/-) mice, showed impaired LCAT activation in vivo, with significant reduction in HDL cholesteryl ester formation. The present results thus identify multiple structural features within the solvent-exposed SF region of apoA-I of nascent HDL essential for optimal LCAT binding and catalytic efficiency.

Indexed as

AnimalsApolipoprotein A-IHumansKineticsLipoproteins, HDLMice, Inbred C57BLPhosphatidylcholine-Sterol O-AcyltransferaseProtein BindingProtein Interaction Domains and MotifsApolipoprotein A-ILipoproteins, HDLPhosphatidylcholine-Sterol O-Acyltransferaseapolipoproteinatherosclerosischolesterolhigh-density lipoprotein (HDL)LCATpost-translational modification (PTM)

Identifiers

PMID26797122
PMCPMC4813583
OpenAlexW2317897385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.